Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.
A key operational challenge in radiopharmaceutical development is the need for a reliable supply of radionuclides for fresh, just-in-time labeling before dosing. This contrasts sharply with conventional drugs that can be manufactured in bulk and stored, adding significant logistical complexity.
In preclinical drug development, choosing the right biological model is the most critical initial decision. Selecting an inappropriate model, such as the wrong PDX or organoid line, guarantees the research program will fail as it will be designed to answer the wrong question from the outset.
In a highly technical field like radiopharmaceuticals, success requires combining distinct capabilities. Crown Bioscience's partnership with Medicine Discovery Catapult merges preclinical modeling expertise with radiolabeling know-how, creating a comprehensive service offering that would be difficult for one organization to build alone.